Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-002811
Filing Date
2025-02-03
Accepted
2025-02-03 19:43:22
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16624
2 JOINT FILING AGREEMENT ex-99-02042025_120225.htm EX-99.1 6670
  Complete submission text file 0001415889-25-002811.txt   25307
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88797 | Film No.: 25584440
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A